CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
dabigatran 110 mg +2 moredrug
Likely dose
dabigatran 110 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00818753
NCT00818753Phase 2Completed
CompareCT.gov

The Safety and Pharmacodynamics of Two Doses of Dabigatran Etexilate in Patients Undergoing Cardiac Catheterization

Boehringer Ingelheim·interventional·Posted Jan 8, 2009·Updated Jun 9, 2014

In Brief

A Phase 2 clinical trial evaluating dabigatran 110 mg, dabigatran 150 mg, and 1 other intervention for Heart Catheterization. Completed, enrolled 53 participants across 4 sites.

Detailed Summary

To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Catheterization
CountriesNetherlands
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 8, 2009
Enrollment StartJan 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.5 years ago

Interventions

dabigatran 110 mgdrug

comparison of different dabigatran dosages with unfractionated heparin

dabigatran 150 mgdrug

comparison of different dabigatran dosages with unfractionated heparin

unfractionated heparindrug

comparison of different dosages dabigatran with unfractionated heparin